Healthcare -
Biotechnology - NASDAQ - IL
$ 0.9458
-2.99 %
$ 8.22 M
Market Cap
-0.48
P/E
1. INTRINSIC VALUE
Balance Sheet
Silexion Therapeutics LTD
| Current Assets | 2.25 M |
| Cash & Short-Term Investments | 1.22 M |
| Receivables | 0 |
| Other Current Assets | 1.03 M |
| Non-Current Assets | 613 K |
| Long-Term Investments | 0 |
| PP&E | 560 K |
| Other Non-Current Assets | 53 K |
| Current Liabilities | 3.52 M |
| Accounts Payable | 929 K |
| Short-Term Debt | 1.16 M |
| Other Current Liabilities | 1.43 M |
| Non-Current Liabilities | 3.33 M |
| Long-Term Debt | 3.33 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Silexion Therapeutics LTD
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 12.6 M |
| Operating Income | -12.6 M |
| Other Expenses | 3.95 M |
| Net Income | -16.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Silexion Therapeutics LTD
| Net Income | -16.5 M |
| Depreciation & Amortization | 25 K |
| Capital Expenditures | -22 K |
| Stock-Based Compensation | 5.86 M |
| Change in Working Capital | -1.58 M |
| Others | 1.63 M |
| Free Cash Flow | -8.42 M |
Wall Street Analysts Price Targets
Silexion Therapeutics LTD
SLXN has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
SLXN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Silexion Therapeutics LTD
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment
New Report Covers Silexion Therapeutics, A Unique Precision Oncology Player New Report Covers Silexion Therapeutics, A Unique Precision Oncology Player
globenewswire.com
- 4 weeks ago
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer
Silexion's new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year Silexion's new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year
globenewswire.com
- 1 month ago
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 million gross funds raised in Q1 2025 Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 million gross funds raised in Q1 2025
globenewswire.com
- 1 month ago
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clinical Trials Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clinical Trials
globenewswire.com
- 1 month ago
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Silexion's new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204's clinical development including plans to initiate human trials in H1 2026 Silexion's new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204's clinical development including plans to initiate human trials in H1 2026
globenewswire.com
- 2 months ago
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation
globenewswire.com
- 3 months ago
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse models; Recent funding strengthens the company's ability to deliver long term value Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse models; Recent funding strengthens the company's ability to deliver long term value
globenewswire.com
- 3 months ago
PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
NEW YORK--(BUSINESS WIRE)---- $SLXN #biotech--PESG Research releases a report covering Silexion Therapeutics' (NASDAQ: SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets. The.
businesswire.com
- 3 months ago
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer
Silexion Therapeutics Corp. SLXN released data on Wednesday from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces primary tumor growth and metastatic spread.
benzinga.com
- 3 months ago
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic Cancer Cells Grow in Their Native Environment Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic Cancer Cells Grow in Their Native Environment
globenewswire.com
- 3 months ago
PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational
NEW YORK--(BUSINESS WIRE)---- $SLXN #biotech--PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, a critical milestone that could continue to position its next-generation RNAi therapy at the forefront of KRAS-driven cancer treatment. With data analysis now underway and initial results expected in the coming weeks, according to the company's latest announcement,.
businesswire.com
- 3 months ago
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks
globenewswire.com
- 3 months ago
8. Profile
Summary
Silexion Therapeutics LTD SLXN
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 8.22 M
Dividend Yield
0.00%
Description
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Contact
The Goldyne Savad Institute of Gene Therapy, Jerusalem, 9112001
https://silexion.com
IPO
Date
Aug. 16, 2024
Employees
11
Officers
Dr. Mitchell Shirvan M.B.A., Ph.D.
Chief Scientific & Development Officer
Ms. Mirit Horenshtein Hadar
EVice President of Finance Affairs, Chief Financial Officer & Secretary
Mr. Ilan Hadar M.B.A.
Chairman & Chief Executive Officer